JINING, China, Aug. 15, 2018 /PRNewswire/ — China YCT International Group, Inc. (OTCQB: CYIG) (the “Company”) today announced its financial results for the three months ended June 30, 2018.

• Total revenues increased by 21.9% year-over-year to $20.89 million with growth in sales from both acer truncatum seed oil and Huoliyuan capsules. The increase in revenues also benefitted from favorable exchange rate between RMB to US$ compared to a year ago.
• Overall gross margin was 42.7%, compared to 40.0% for the same period of the prior fiscal year. The increase in overall gross margin was mainly due to higher gross margin for acer truncatum seed oil as a result of decreased raw material, packaging and manufacturing costs.
• Net income attributable to the Company was $4.49 million, or $0.15 per share, compared to $3.81 million, or $0.13 per share, for the same period of the prior fiscal year.

“We started the new fiscal year on a high note with revenues and net income increasing by 21.9% and 17.8%, respectively, for the first fiscal quarter that ended June 30, 2018. Gross and operating margins also increased on a year-over-year basis. The acer truncatum seed oil segment was particularly strong, with revenues growing by 81.3% to $5.25 million. Gross margin for acer truncatum seed oil also reached record level of 60.5% for the fiscal quarter ended June 30, 2018,” said Mr. Tinghe Yan, Chairman and Chief Executive Officer of the Company.

“As our order trend suggests continuing growth momentum, we are optimistic about the near-term outlook of our business and believe that we can extend our streak of five consecutive years of top-line growth in fiscal year 2019,” concluded Mr. Yan.

Fiscal Quarter Ended June 30, 2018 Financial Results

Revenues

For the three months ended June 30, 2018, total revenues increased by $3.75 million, or 21.9%, to $20.89 million from $17.13 million for the same period of the prior fiscal year. The increase in total revenues was mainly due to increase in sales for acer truncatum seed oil and also benefited from RMB appreciation versus US$ compared to a year ago.

Revenues from health care products increased by $0.17 million, or 2.1%, to $8.01 million for the three months ended June 30, 2018 from $7.85 million for the same period of the prior fiscal year. The revenue from sales of health care products measured in RMB decreased by 5.0% but was offset by a 7.1% increase due to favorable US currency exchange rates. The decrease in sales of the health care products in RMB was primarily due to decreases in sales of other traditional health care products. 

Revenues from Huoliyuan capsules increased by $1.24 million, or 19.3%, to $7.63 million  for the three months ended June 30, 2018 from $6.40 million for the same period of the prior fiscal year. The increase in sales of Huoliyuan capsules was primarily due to improved market share performance.

Revenues from acer truncatum seed oil increased by $2.35 million, or 81.3%, to $5.25 million for the three months ended June 30, 2018 from $2.89 million for the same period of the prior fiscal year. The increase in sales of acer truncatum seed oil was primarily due to continuing promotions of acer truncatum seed oil at conferences highlighting features and benefits of the product to our distributors and customers. Since July 2015, the Company has produced and sold acer truncatum seed oil extracted from the acer truncatum pods purchased from third party vendors. Our crops of acer truncatum pods will not be ready for production until approximately the fall of 2018. 

The sales of health care products, Huoliyuan capsules, and acer truncatum Parliament seed oil accounted for 38.3%, 36.5%, and 25.1%, respectively, of total revenues for the three months ended June 30, 2018 , compared to 45.8%, 37.3%, and 16.9%, respectively, for the same period of the prior fiscal year.

The following table summarizes revenues and gross profit by products for the three months ended June 30, 2018 and 2017, respectively:

Cost of Goods Sold

Cost of goods sold comprised primarily the cost of finished goods purchased from Shandong Yongchuntang, raw materials purchased from third party vendors, and the manufacturing cost of acer truncatum seed oil and Huoliyuan capsules. For the three months ended June 30, 2018, total cost of goods sold increased by $1.68 million, or 16.3%, to $11.96 million from $10.29 million for the same period of the prior fiscal year. As a percentage of revenues, total cost of goods sold was 57.3% for the three months ended June 30, 2018, compared to 60.0% for the same period of the prior fiscal year. The decrease was primarily due to decreased raw material, packaging and manufacturing costs for acer truncatum seed oil.

Cost of goods sold for health care products, Huoliyuan capsules, and acer truncatum seed oil were $4.45 million, $5.44 million and $2.07 million, respectively for the three months ended June 30, 2018, compared to $4.34 million, $4.34 million, and $1.61 million, respectively, for the same period of the prior fiscal year.

Gross Profit

Gross profit increased by $2.08 million, or 30.3%, to $8.92 million for the three months ended June 30, 2018, from $6.85 million for the same period of the prior fiscal year. Gross profit for health care products, Huoliyuan capsules, and acer truncatum Parliament seed oil were $3.56 million, $2.19 million, and $3.17 million, respectively, for the three months ended June 30, 2018, compared to $3.51 million, $2.05 million, and $1.29 million, respectively, for the same period of the prior fiscal year.

Overall gross margin was 42.7%, with gross margins for health care products, Huoliyuan capsules, and acer truncatum seed oil being 44.4%, 28.7%, and 60.5%, respectively, for the three months ended June 30, 2018. Overall gross margin was 40.0%, and gross margins for health care products, Huoliyuan capsules, and acer truncatum seed oil were 44.7%, 32.1%, and 44.5%, respectively, for the same period of the prior fiscal year. The increase in overall gross margin was mainly due to acer truncatum seed oil as a result of decreased raw material, packaging, and manufacturing costs.

Operating Expenses

Selling expenses consist primarily of sales commissions, advertising and promotion, freight charges, and related compensation. For the three months ended June 30, 2018, selling expenses increased by $0.16 million, or 12.6%, to $1.40 million, from $1.24 million for the same period of the prior fiscal year. The increase in selling expenses was primarily due to increases in shipping cost and sales commission from increased sales and salary expense.

General and administrative expenses increased by $0.17 million, or 19.0%, to $1.08 million for the three months ended June 30, 2018 from $0.91 million for the same period of the prior fiscal year. The increase in general and administrative expenses was primarily due to the increase in depreciation and consulting expenses.

Research and development expenses were $0.32 million for the three months ended June 30, 2018, compared to $0.06 million for the same period of the prior fiscal year. The increase in research and development expenses was mainly due to the increased cost of the materials used by the R&D department. As of June 30, 2018, the Company had a staff of 27 in the R&D department.

As a result, total operating expenses increased by $0.59 million, or 26.5%, to $2.80 million for the three months ended June 30, 2018, from $2.21 million for the same period of the prior fiscal year.

Operating Income

Total operating income increased by $1.49 million, or 32.1%, to $6.13 million for the three months ended June 30, 2018, from $4.64 million for the same period of the prior fiscal year. The increase in total operating income was mainly a result of increased gross profit, partially offset by increased operating expenses. Operating margin was 29.3% for the three months ended June 30, 2018, compared to 27.1% for the same period of the prior fiscal year.

Income before Income Taxes

Interest income was $40,073 for the three months ended June 30, 2018, compared to $25,103 for the same period of the prior fiscal year. The Company also booked gain on disposal of acer truncatum bunge plants of $0.57 million for the three months ended June 30, 2017.

Income before income tax provisions increased by $0.93 million, or 17.8%, to $6.17 million for the three months ended June 30, 2018, from $5.24 million for the same period of the prior fiscal year.

Net Income

Income tax expense increased by $0.23 million, or 17.8%, to $1.54 million for the three months ended June 30, 2018, from $1.31 million for the same period of the prior fiscal year.

Net income increased by $0.70 million, or 17.8%, to $4.63 million for the three months ended June 30, 2018, from $3.93 million for the same period of the prior fiscal year.

After the deduction of non-controlling interest, net income attributable to the Company was $4.49 million, or $0.15 per basic and diluted share for the three months ended June 30, 2018, compared to $3.81 million, or $0.13 per basic and diluted share, for the same period of the prior fiscal year.

Liquidity and Capital Resources

As of June 30, 2018, the Company had cash and cash equivalents of $27.86 million, and inventories of $3.16 million, compared to $25.35 million, and $2.38 million, respectively, as of March 31, 2018. Total working capital was $31.78 million as of June 30, 2018, compared to $28.08 million as of March 31, 2018.

Net cash provided by operating activities was $4.16 million for the three months ended June 30, 2018, compared to $5.55 million for the same period of the prior fiscal year. Net cash used in investing activities was $0.26 million for the three months ended June 30, 2018, compared to $1.21 million for the same period of the prior fiscal year. Net cash provided by financing activities was $nil for the three months ended June 30, 2018 and 2017, respectively. 

Recent Developments

On July 17, 2018, the Company announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed public offering of shares of its common stock, par value $0.001 per share, for gross proceeds of $7,500,000, excluding the proceeds from the sale of additional shares of common stock to cover over-allotments, if any. The number of shares to be offered and the price range for the proposed offering have not yet been determined. China YCT International Group, Inc. has applied to list its common stock on The Nasdaq Capital Market. Maxim Group LLC will act as the sole book-running manager for the proposed offering.

About China YCT International Group, Inc.

Based in Jining, Shandong Province and founded in January 1989, China YCT International Group, Inc., through its subsidiaries, engages in the business of (i) distributing health care supplement products manufactured by Shandong Yongchuntang Group Co., Ltd. in the PRC, (ii) developing, manufacturing, and selling Huoliyuan capsules, a prescription medicine, (iii) developing acer truncatum bunge planting bases, and manufacturing and selling acer truncatum bunge seed oil in the PRC. Acer truncatum bunge plants are a species of maple tree. For more information about the Company, please visit http://zgyct.yongchuntang.com.

Forward-Looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulations, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by this cautionary statement and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

At the Company:

Zecheng Shao, Vice President
Phone: +86-156-5377-2006
Email: zc_shao@126.com

Investor Relations:

Tony Tian, CFA
Weitian Group LLC
Phone: +1-732-910-9692
Email: ttian@weitianco.com

View original content:http://www.prnewswire.com/news-releases/china-yct-international-group-reports-financial-results-for-the-fiscal-quarter-ended-june-30-2018-300696735.html